News

Spanish healthcare company Grifols announced that Singapore’s wealth fund GIC agreed to invest about $1bn in Grifols’ wholly owned US subsidiary Biomat USA. As part of the definitive

Global biopharmaceutical firm Sanofi has launched a dedicated vaccines mRNA Center of Excellence to accelerate development and delivery of next-generation vaccines. The company has also announced plans to

German generic drug manufacturer STADA Group has agreed to acquire a portfolio of well-established consumer healthcare brands from biopharmaceutical firm Sanofi to expand its European Consumer Healthcare portfolio.

Johnson & Johnson (J&J) has reached a $230m agreement to settle the opioid-related claims with the New York State and its participating subdivisions Nassau County and Suffolk County.

The deal is made possible via AbbVie’s exercise of its exclusive right to purchase TeneoOne and TNB-383B. The acquisition option was part of a strategic alliance formed with

The indication is for intravenous use of the drug in both adult and paediatric patients aged two years and above who are on systemic corticosteroids and need supplemental

Lecanemab is an experimental humanised antibody that targets amyloid beta aggregates known as protofibril. The drug was developed as part of a collaboration between Eisai and BioArctic. The

The demerger is scheduled to occur mid-next year. Before the separation, GSK is set to obtain a dividend of up to £8bn from Consumer Healthcare. With a portfolio

ViiV Healthcare has signed a global collaboration and license agreement with Halozyme Therapeutics to develop “ultra-long-acting” medicines for HIV. The deal gives exclusive access to Halozyme’s ENHANZE drug